Amends TCA Title 33; Title 53; Title 63 and Title 68.

ON APRIL 16, 2024, THE HOUSE ADOPTED AMENDMENT #1 AND PASSED HOUSE BILL 2093, AS AMENDED.<br /> <br /> AMENDMENT #1 rewrites the bill to, instead, relative to present law on the use of buprenorphine products, authorize a healthcare provider licensed as a nurse or physician assistant to prescribe a buprenorphine product as approved by the FDA for use in recovery or medication-assisted treatment if the following applies:<br /> <br /> (1) The provider writes prescriptions of buprenorphine products to 100 or fewer patients at any given time; however, such limit is 250 or fewer patients if the provider practices in a nonresidential office-based opiate treatment facility, as defined in state law, that is accredited by a nationally or internationally recognized accrediting body, including the commission on the accreditation of rehabilitation facilities (CARF) or the joint commission; and<br /> <br /> (2) When providing direct supervision, as required by state law, the physician does not oversee more than two providers licensed as a nurse or physician assistant at one time during clinical operations; however, if the physician practices in a nonresidential office-based opiate treatment facility that is accredited by a nationally or internationally recognized accrediting body such as CARF or the joint commission, the physician may oversee no more than five providers licensed as nurses or physician assistants, and at no time may the physician oversee the treatment of more than 500 patients under this (2) at any one time during clinical operations.<br />